Table 3.
Treatment-related common adverse events in this meta-analysis.
| Adverse events | All grades | Grade ≥ 3 | ||
|---|---|---|---|---|
| RR (95% CI) | P | RR (95% CI) | P | |
| Anemia | 0.35 (0.27, 0.46) | ≤0.001 | 0.34 (0.23, 0.49) | ≤0.001 |
| Alopecia | 0.12 (0.08, 0.19) | ≤0.001 | 0.29 (0.11, 0.76) | 0.012 |
| Arthralgia | 1.05 (0.80, 1.38) | 0.728 | 1.49 (0.79, 2.84) | 0.219 |
| Neutropenia | 0.16 (0.11, 0.25) | ≤0.001 | 0.22 (0.14, 0.34) | ≤0.001 |
| Diarrhea | 0.82 (0.70, 0.97) | 0.020 | 0.97 (0.68, 1.38) | 0.859 |
| Dyspnea | 0.99 (0.84, 1.17) | 0.943 | 0.95 (0.65, 1.38) | 0.790 |
| Stomatitis | 0.31 (0.20, 0.48) | ≤0.001 | 0.31 (0.14, 0.70) | 0.005 |
| Nausea | 0.60 (0.49, 0.73) | ≤0.001 | 0.76 (0.54, 1.05) | 0.098 |
| Pyrexia | 1.23 (1.03, 1.48) | 0.024 | 0.92 (0.40, 2.10) | 0.844 |
| Asthenia | 0.69 (0.60, 0.79) | ≤0.001 | 0.55 (0.39, 0.79) | ≤0.001 |
| Rash | 1.56 (1.26, 1.92) | ≤0.001 | 1.31 (0.80, 2.15) | 0.277 |
| Neuropathy | 0.39 (0.26, 0.60) | ≤0.001 | 0.81 (0.44, 1.49) | 0.504 |
| Fatigue | 0.77 (0.70, 0.85) | ≤0.001 | 0.55 (0.42, 0.72) | ≤0.001 |
| Vomit | 0.61 (0.45, 0.81) | ≤0.001 | 0.66 (0.44, 0.98) | 0.040 |
| Constipation | 0.63 (0.48, 0.83) | ≤0.001 | 0.78 (0.32, 1.88) | 0.575 |
| Pneumonitis | 2.44 (1.23, 4.87) | 0.011 | 1.67 (0.94, 2.96) | 0.080 |
| Pruritus | 3.46 (2.67, 4.49) | ≤0.001 | 0.90 (0.27, 3.00) | 0.869 |
| Mucosal Inflammation | 0.29 (0.18, 0.44) | ≤0.001 | 0.34 (0.18, 0.66) | 0.002 |
| Decreased Appetite | 0.19 (0.08, 0.42) | ≤0.001 | 0.76 (0.49, 1.19) | 0.228 |
| Decreased Neutrophil Count | 0.17 (0.09, 0.22) | ≤0.001 | 0.17 (0.09, 0.35) | ≤0.001 |
| Decreased White-Cell Count | 0.19 (0.08, 0.42) | ≤0.001 | 0.19 (0.08, 0.49) | ≤0.001 |